Lupin gains 3% on USFDA approval for generic Corgard tablets

The company has received final approval from the US health regulator to market generic Nadolol tablets, used for treatment of hypertension, in the American market.

Lupin was trading 3% higher at Rs 1,068 on BSE at 09:30 AM after the pharmaceutical company said it has received final approval from the US health regulator to market generic Nadolol tablets, used for treatment of hypertension, in the American market.

“The company has received final approval for its Nadolol tablets USP 20 mg, 40 mg and 80 mg from the United States Food and Drug Administration (USFDA) to market a generic version of US WorldMeds, LLC Corgard Tablets, 20 mg, 40 mg and 80 mg,” Lupin said in a press release on Monday after market hours.